A recent study found that thinking about bigger meals can actually cut back on snacking.

Published Date: 08 Mar 2023

The so-called "meal reminder effect" can reduce the amount of food a person eats later. Researchers from the University of Cambridge studied the impact of emotions on mindful eating.

Read Full News

Latest News

Study shows Ozempic could help dialysis patients qualify for kidney transplants

Obesity is one of the biggest barriers preventing patients with end-stage kidney disease from receiving a life-saving kidney transplant. New research from Saint Louis University School of Medicine and SSM Health physicians ...

How do I know if my kid is worrying about food and their body too much? And what should I say?

Eating disorders are most likely to develop in young people aged between 12 and 25.

Understudied eating disorder matches anorexia, bulimia severity

A diagnosis often viewed as less serious than anorexia and bulimia—and the most common eating disorder worldwide—can cause just as much harm, a new study has found.

Popular weight-loss drugs show added heart protection for diabetes patients

Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School have demonstrated this ...

Diabetes drug reduced irregular heartbeat events in overweight/obese adults with AFib

People with atrial fibrillation (AFib) and obesity may have fewer episodes of AFib after ablation if they take the diabetes medication metformin in addition to standard care, according to a preliminary, late-breaking science ...

Mandatory nutrient warning labels could prevent 100,000+ obesity-related deaths

Researchers from the University of Liverpool have found that making front-of-pack nutrition labeling mandatory could significantly reduce obesity rates and save thousands of lives across England.

Todays Updates

This Week on NeurologyLive® — December 22, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Remyelinating Agent PIPE-307 Falls Short in Phase 2 Trial of Relapsing Multiple Sclerosis Marco Meglio

Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.

Brain-Penetrant Molecule GT-02287 Demonstrates Reversal of Glucosylsphinogosine in Parkinson Disease Marco Meglio

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.

Daily Lemon Water Lowers Serum Urate Levels in Patients With Hyperuricemia

Daily Lemon Water Lowers Serum Urate Levels in Patients With Hyperuricemia

COPD in 2025: Year in Review

COPD in 2025: Year in Review

FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector

FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector

Nephrology in 2025: Year in Review

Nephrology in 2025: Year in Review

Todays Updates

This Week on NeurologyLive® — December 22, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Remyelinating Agent PIPE-307 Falls Short in Phase 2 Trial of Relapsing Multiple Sclerosis Marco Meglio

Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.

Brain-Penetrant Molecule GT-02287 Demonstrates Reversal of Glucosylsphinogosine in Parkinson Disease Marco Meglio

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.

Daily Lemon Water Lowers Serum Urate Levels in Patients With Hyperuricemia

Daily Lemon Water Lowers Serum Urate Levels in Patients With Hyperuricemia

COPD in 2025: Year in Review

COPD in 2025: Year in Review

FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector

FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector

Nephrology in 2025: Year in Review

Nephrology in 2025: Year in Review

Latest News

Obesity is one of the biggest barriers preventing patients with end-stage kidney disease from receiving a life-saving kidney transplant. New research from Saint Louis University School of Medicine and SSM Health physicians ...

Eating disorders are most likely to develop in young people aged between 12 and 25.

A diagnosis often viewed as less serious than anorexia and bulimia—and the most common eating disorder worldwide—can cause just as much harm, a new study has found.

Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School have demonstrated this ...

People with atrial fibrillation (AFib) and obesity may have fewer episodes of AFib after ablation if they take the diabetes medication metformin in addition to standard care, according to a preliminary, late-breaking science ...

Researchers from the University of Liverpool have found that making front-of-pack nutrition labeling mandatory could significantly reduce obesity rates and save thousands of lives across England.

News All Time

Five reasons we shouldn't 'compliment' people who lose weight

"You look so great! Have you lost weight?"

Nearly 70% of US adults meet new definition of obesity, study finds

The prevalence of obesity in the United States could rise sharply under a definition of obesity released earlier this year by the Lancet Diabetes and Endocrinology Commission.

BMI shouldn't be the only way to assess who can access weight-loss drugs

About 1 in 3 Australian adults (32%) has a body-mass index (BMI) of 30 or above. A further 34% has a BMI of 25 or above.

Diets high in ultra-processed foods are bad for us, so why are we eating more?

Aussies eat more ultra-processed foods than ever before, with busy lifestyles and personal choices often taking the blame as casual factors.

Weight loss drug stigma shows society still holds negative attitudes towards body weight and obesity

Since Wegovy received approval as a weight loss treatment in 2021, there has been huge demand for GLP-1 drugs. These drugs reduce hunger and suppress the "food noise" that can make it difficult to lose weight.

Two in three people with chronic pain turn to comfort eating

More than two-thirds of people living with chronic pain reach for chocolate or other comfort foods to cope, with new research showing that eating offers pleasure, distraction and relief from negative emotions during pain ...

Gaps and opportunities in precision medicine approach to obesity treatment identified

A new report led by researchers at Pennington Biomedical Research Center underscores the growing potential of precision medicine to transform how obesity is prevented, diagnosed and treated, while also illuminating key gaps ...

Think your BMI reflects your health? Think again, study warns

As new Statistics Canada data reveals that two-thirds of Canadians are considered overweight or obese, researchers are urging the public and policymakers to rethink how we define and measure health—starting with one of ...

Use of weight loss drugs before bariatric surgery has soared in recent years, study finds

New research findings show a significant increase in the use of weight loss drugs among patients undergoing metabolic and bariatric surgery, signaling an evolution in the management of obesity and type 2 diabetes.

Research highlights the need for culturally specific screening tools

Despite research finding a higher prevalence of eating disorders among Aboriginal youth in Australia, new research from Edith Cowan University (ECU) published in the Journal of Eating Disorders has revealed a lack of culturally ...

Semaglutide, tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidance

Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity and its complications from ...

Weight-loss surgery could help boost work productivity

A new international QUT-led study found that bariatric surgery improves work productivity and employment rates in the short term—but these gains may not last beyond five years without targeted support.

Reducing risk of eating disorders by controlling peer and family pressures

Weight-related peer teasing is a strong predictor of disordered eating behaviors in adolescents, particularly those at higher genetic risk, new research shows.

Study suggests new drug for weight loss may cause fewer side effects

A new Penn Nursing study suggests that the weight-loss drug tirzepatide may cause fewer side effects like nausea and vomiting than the drug semaglutide. This research, published in Science Advances, was conducted using preclinical ...

Weight loss treatments for people with diabetes and obesity could lower the risk of obesity-related cancers

Weight loss treatments, including medication and surgical procedures, may help lower the risk of obesity-related cancers in people with obesity and type 2 diabetes, a new study shows.

Too heavy for medical care: Over 40% of specialty clinics turn away patients weighing 465 pounds

Patients weighing 450 pounds or more face barriers and discrimination when scheduling or attending doctor visits at subspecialty practices, reports a new Northwestern Medicine study.

Recommended News For You

Clinical Evidence Shows Venetoclax Combo Is Safe and Effective in AML Patients 80 Years of Age and Up.

CAR-T Warning for Secondary Malignancies: Warranted or Not?

Optimizing Sequencing of BCMA-Directed Therapies in Myeloma

Big Drop in Cervical Cancer Deaths; Publication Hijackers; A Win for CRC Home Tests

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

After a plane crash, a surgeon dies; Austin is released from the hospital; and an animal pandemic spreads.

Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer

Recommended Articles For You

Exploring the Causes and Treatments of Thrombocytopenia: A Comprehensive Guide 

Unlocking the Potential of Immune Checkpoint Inhibitors: A Pioneering Case Series on the Role of Immunotherapy in Microsatellite-Instability-High Colorectal Cancer 

New Frontiers in Diagnosing and Managing Myelodysplastic Syndromes (MASLD) 

Essential Oncology Tools: Risk Assessment, Telehealth, AI, and Monitoring 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Simultaneously targeting lysosomal enzyme and KRAS-MAPK pathway eradicates pancreatic tumors in preclinical models

2.

Shorter, less intense regimen still effective for HPV-linked throat cancer, study shows

3.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

4.

In leukemia, allogeneic HCT is beneficial following primary induction failure.

5.

Trial Questions Role of Dual Immunotherapy in First-Line NSCLC

1.

Targeting the Tumor Microenvironment: Next-Generation Strategies for Immuno-Oncology Success

2.

Everything You Need to Know About CA 19-9 and Cancer Diagnosis

3.

Survival Rate Dynamics in Hematologic and Solid Malignancies

4.

Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies

5.

Neoadjuvant Radiotherapy & Endocrine Therapy in ER+ Breast Cancer Treatment

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Complexities of Ph Negative ALL - Part XIV

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III

3.

Navigating the Complexities of Ph Negative ALL - Part XIII

4.

Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot